Tag - CWBR

Markets

Chardan starts CohBar at buy; PT $3

Chardan Research launched coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and price target of $3. The stock closed at $1.29 on Dec. 16. “We expect that Cohbar’s unique pipeline of mitochondrial derived...

December 17, 2020

Developments

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

CohBar (NASDAQ:CWBR) dosed first subjects with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for non-alcoholic steatohepatitis (NASH) and obesity. The Phase 1b study is designed to evaluate one dose...

August 24, 2020

Markets

CohBar added to Russell 2000 index; raises $4.4-million in ATM offering

CohBar (NASDAQ:CWBR) was added to the small-cap Russell 2000 index during its latest reconstitution. The company also sold common stock through its existing at-the-market (ATM) offering, with net proceeds of about $4.4...

June 30, 2020

Markets

Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

May 27, 2020

Tag - CWBR

Chardan starts CohBar at buy; PT $3

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

CohBar added to Russell 2000 index; raises $4.4-million in ATM offering

Brookline starts CohBar at buy; PT $10

General

More